Motley Fool's Brian Orelli weighed in on BioSante Pharmaceuticals' $100,000 upfront deal with the John P. Hussman Foundation for melanoma vaccine development, saying he considered the deal less than stellar. While the company could get up to $39 million in milestone payments, it didn't partner with a big name company, although there are several such players in the melanoma arena. One probable reason? Immunotherapies are still deemed too risky. Article